ASH 2020 | Multiple myeloma highlights from ASH 2020
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares his highlights from ASH 2020 in multiple myeloma, picking out BCMA-targeted approaches including chimeric antigen receptor (CAR) T-cell therapies, antibody-drug conjugates and bispecific T-cell engagers. Dr Costa also discusses three trials in relapsed/refractory multiple myeloma, including a Phase I study (NCT03399799) investigating talquetamab, a bispecific antibody that binds GPRC5D and CD3, the Phase I GO39775 trial (NCT03275103) of the bispecific T-cell engager BFCR4350A, and updated results from a Phase 1 trial (NCT03145181) of the BCMA-targeting bispecific antibody therapy teclistamab. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Dr Luciano Costa, MD, PhD, has received research funding from Amgen and Janssen; and has received honoraria from Amgen, Janssen, BMS and Sanofi.
